MedTrace Logo

COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial

NCT02404376 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 378

Last updated 2020-11-03

No results posted yet for this study

Summary

Remote ischemic conditioning (RIC) and intravenous exenatide administered immediately before primary angioplasty have been found to limit infarct size in patients with STEMI (ST segment elevation myocardial infarction), but the reduction is limited. This study investigates whether a combination therapy including both therapies is more effective.

Conditions

  • ST Elevation Acute Myocardial Infarction

Interventions

DRUG

Exenatide

Intravenous administration of Exenatide

OTHER

Remote Ischemic Conditioning (RIC)

Remote ischemic conditioning with a cuff in the arm

DRUG

Placebo

Intrevenous administration of Placebo

Sponsors & Collaborators

  • Hospital Universitari Vall d'Hebron Research Institute

    lead OTHER

Principal Investigators

  • Ignacio Ferreira González, MD, PhD · Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2019-08-31
Completion
2020-06-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02404376 on ClinicalTrials.gov